Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

Detalles Bibliográficos
Autores principales: Schaer, David, Li, Yanxia, Castaneda, Stephen, Inigo, Ivan, Surguladze, David, Xu, Xiaohong, Nugent, Desiree, Murphy, Mary, Hall, Gerald, Benhadji, Karim, Guba, Susan, Li, Yiwen, Kalos, Michael, Driscoll, Kyla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652527/
http://dx.doi.org/10.1186/2051-1426-3-S2-P402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652527/
http://dx.doi.org/10.1186/2051-1426-3-S2-P402

Ejemplares similares